公开(公告)号：US20150004695A1

公开(公告)日：2015-01-01

申请号：US14314873

申请日：2014-06-25

Applicant: FUJIFILM Corporation

Inventor： Naoyuki NISHIKAWA ,  Kyoko SENGA ,  Yuuki INOUE ,  Yuko IGARASHI

IPC: C12N15/113

CPC classification number: C12N15/111 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/32

Abstract: The present invention provides a lipid particle which has low cytotoxicity, can stably hold a nucleic acid molecule outside a cell (in blood), and can escape from an endosome and rapidly release the nucleic acid in the cytoplasm; a nucleic acid transfer carrier; a compound for manufacturing a nucleic acid transfer carrier; a method for manufacturing a lipid particle; and a gene transfer method. The lipid particle contains, as constituents, a phospholipid having one or more amino groups and one or more nitrogen-containing heterocyclic groups, a neutral lipid not containing a nitrogen-containing heterocyclic group, a sterol, and a nucleic acid.

Abstract translation: 本发明提供了具有低细胞毒性的脂质颗粒，可以将核酸分子稳定地保持在细胞外（血液中），并且可以从内体中逸出并迅速释放细胞质中的核酸; 核酸转运载体; 用于制造核酸转移载体的化合物; 一种制备脂质颗粒的方法; 和基因转移方法。 脂质颗粒含有具有一个或多个氨基和一个或多个含氮杂环基的磷脂，不含氮杂环基的中性脂质，固醇和核酸。

公开(公告)号：US20190022108A1

公开(公告)日：2019-01-24

申请号：US16137493

申请日：2018-09-20

Applicant: FUJIFILM CORPORATION

Inventor： Hiroki TANISAKA ,  Kyoko SENGA ,  Shuhei OSAKA

IPC: A61K31/565 ,  A61K9/08 ,  A61K47/10 ,  A61K47/44 ,  A61K9/00

Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition. (A) A content of benzyl benzoate is less than 1% by mass with respect to the entire mass of the pharmaceutical composition. (B) A content of the nonaqueous carrier is 40% to 75% by mass with respect to the entire mass of the pharmaceutical composition.

公开(公告)号：US20190070195A1

公开(公告)日：2019-03-07

申请号：US16181248

申请日：2018-11-05

Applicant: FUJIFILM CORPORATION

Inventor： Hiroki TANISAKA ,  Kyoko SENGA

IPC: A61K31/565 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44 ,  A61K9/00

Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of 4.5% by mass to 10.0% by mass with respect to the entire mass of the pharmaceutical composition, at least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol in an amount of 8% by mass to 23% by mass with respect to the entire mass of the pharmaceutical composition, benzyl alcohol in an amount of 5% by mass to 24% by mass with respect to the entire mass of the pharmaceutical composition, benzyl benzoate in an amount of 8% by mass to 19% by mass with respect to the entire mass of the pharmaceutical composition, and castor oil, and in which a content of ethanol is less than 1% by mass with respect to the entire mass of the pharmaceutical composition, and a content of benzoic acid is less than 1% by mass with respect to the entire mass of the pharmaceutical composition.

公开(公告)号：US20170042810A1

公开(公告)日：2017-02-16

申请号：US15335640

申请日：2016-10-27

Applicant: FUJIFILM Corporation

Inventor： Takeshi MATSUMOTO ,  Kohei ONO ,  Makoto ONO ,  Kyoko SENGA

IPC: A61K9/127 ,  A61K31/519 ,  A61K31/7068

CPC classification number: A61K9/127 ,  A61K9/1278 ,  A61K31/519 ,  A61K31/7068 ,  A61K45/00 ,  A61K47/24 ,  A61K47/28

Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a drug in a dissolved state, an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase, and a release rate of the drug from each of the liposomes is 10%/24 hr to 70%/24 hr in blood plasma at 37° C.; and a method for producing the same.

Abstract translation: 本发明提供一种脂质体组合物，其具有实际上所需的长期保存稳定性，并且由于能够通过使内部水分适当地控制药物的释放性，其具有几十小时数量级的药物的释放速率 相超渗透 及其制造方法。 根据本发明，可以提供一种脂质体组合物，其包括脂质体，其各自具有构成外部水相的内部水相和水溶液，并且其中分散有脂质体，其中每个脂质体包封 处于溶解状态的药物，内部水相的渗透压相对于外部水相的渗透压为2倍〜8倍，并且来自各脂质体的药物的释放速度为10％/ 24小时至70％/ 24小时在37℃的血浆中。 及其制造方法。